Page Updated May 29, 2024

Marta Batus, MD

Page Written by

Terri Heimann Oppenheimer

Page Edited by Patient Advocate

Dave Foster

Fact Checked

Dr. Batus is a medical oncologist at Rush University in Chicago, Illinois.  Her practice largely consists of caring for patients diagnosed with all types of lung cancer, sarcoma, and melanoma. She works as part of a multidisciplinary team, creating the right treatment plan for each patient based on their condition and their individual goals. Treatment plans may include surgery, chemotherapy, and radiation therapy.

Dr. Batus is board-certified in Medical Oncology. She feels that the most gratifying part of oncology is the patient-physician relationship that is established with patients.[1]

Education and Career

Dr. Batus earned her medical degree at Rush Medical College in Chicago, Illinois, and remained there for her internship and residence in Internal Medicine. She then completed her training during her fellowship in Hematology and Oncology at Rush University Medical Center.[1]

Research

Dr. Batus is actively involved in clinical trials and research at Rush University, specifically focusing on topics including lung cancer and non-small cell lung cancer, sarcoma, and soft-tissue sarcoma. She has authored and co-authored over 52 publications. 

Dr. Batus’ recent publications include:[2]

• Marta Batus on the New Direct-to-Consumer Advertising for Nivolumab, and Its Impact on Oncology Practice. Batus M. Oncology (Williston Park). 2016 Jun;30(6):506, 523. PMID: 27306707
• Treatment of advanced squamous cell carcinoma of the lung: a review.Derman BA, Mileham KF, Bonomi PD, Batus M, Fidler MJ. Transl Lung Cancer Res. 2015 Oct;4(5):524-32. doi: 10.3978/j.issn.2218-6751.2015.06.07. PMID: 26629421
• PET-CT staging affects time to treatment in sarcoma. Lee L, Kazmer A, Colman MW, Gitelis S, Batus M, Blank AT. Surg Oncol. 2022 May;41:101732. doi: 10.1016/j.suronc.2022.101732. Epub 2022 Feb 24. PMID: 35235893

• Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Batus M, Fidler MJ, Bonomi PD. Expert Rev Anticancer Ther. 2010 Oct;10(10):1589-99. doi: 10.1586/era.10.104. PMID: 20942630

• Optimal management of metastatic melanoma: current strategies and future directions.Batus M, Waheed S, Ruby C, Petersen L, Bines SD, Kaufman HL. Am J Clin Dermatol. 2013 Jun;14(3):179-94. doi: 10.1007/s40257-013-0025-9. PMID: 23677693

Terri Heimann Oppenheimer

Writer

Terri Oppenheimer has been writing about mesothelioma and asbestos topics for over ten years. She has a degree in English from the College of William and Mary. Terri’s experience as the head writer of our Mesothelioma.net news blog gives her a wealth of knowledge which she brings to all Mesothelioma.net articles she authors.

Connect with Terri Heimann Oppenheimer

Dave Foster

Page Editor

Dave has been a mesothelioma Patient Advocate for over 10 years. He consistently attends all major national and international mesothelioma meetings. In doing so, he is able to stay on top of the latest treatments, clinical trials, and research results. He also personally meets with mesothelioma patients and their families and connects them with the best medical specialists and legal representatives available.

Connect with Dave Foster